9330 related articles for article (PubMed ID: 1653780)
1. Non-myelotoxic antitumour effects of L-dopa, buthionine sulphoximine and tamoxifen on neuroblastoma cells in vitro and in vivo.
Busse E; Bartsch O; Kornhuber B
J Cancer Res Clin Oncol; 1991; 117(5):449-53. PubMed ID: 1653780
[TBL] [Abstract][Full Text] [Related]
2. Sensitivity of human melanoma cells to L-dopa and DL-buthionine (S,R)-sulfoximine.
Kable EP; Favier D; Parsons PG
Cancer Res; 1989 May; 49(9):2327-31. PubMed ID: 2706620
[TBL] [Abstract][Full Text] [Related]
3. Relationship between melanogenesis, glutathione levels and melphalan toxicity in human melanoma cells.
Benathan M; Alvero-Jackson H; Mooy AM; Scaletta C; Frenk E
Melanoma Res; 1992 Dec; 2(5-6):305-14. PubMed ID: 1337997
[TBL] [Abstract][Full Text] [Related]
4. Buthionine sulphoximine alone and in combination with melphalan (L-PAM) is highly cytotoxic for human neuroblastoma cell lines.
Anderson CP; Tsai J; Chan W; Park CK; Tian L; Lui RM; Forman HJ; Reynolds CP
Eur J Cancer; 1997 Oct; 33(12):2016-9. PubMed ID: 9516845
[TBL] [Abstract][Full Text] [Related]
5. Enhanced melphalan cytotoxicity in human ovarian cancer in vitro and in tumor-bearing nude mice by buthionine sulfoximine depletion of glutathione.
Ozols RF; Louie KG; Plowman J; Behrens BC; Fine RL; Dykes D; Hamilton TC
Biochem Pharmacol; 1987 Jan; 36(1):147-53. PubMed ID: 3801051
[TBL] [Abstract][Full Text] [Related]
6. Effects of tyrosinase activity on the cytotoxicity of 3,4-dihydroxybenzylamine and buthionine sulfoximine in human melanoma cells.
Prezioso JA; Fitzgerald GB; Wick MM
Pigment Cell Res; 1990; 3(2):49-54. PubMed ID: 2117268
[TBL] [Abstract][Full Text] [Related]
7. Buthionine sulfoximine and myeloablative concentrations of melphalan overcome resistance in a melphalan-resistant neuroblastoma cell line.
Anderson CP; Seeger RC; Satake N; Monforte-Munoz HL; Keshelava N; Bailey HH; Reynolds CP
J Pediatr Hematol Oncol; 2001 Nov; 23(8):500-5. PubMed ID: 11878777
[TBL] [Abstract][Full Text] [Related]
8. Effects of glutathione depletion by buthionine sulfoximine on the sensitivity of EMT6/SF cells to chemotherapy agents or X radiation.
Shrieve DC; Harris JW
Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1171-4. PubMed ID: 3744936
[TBL] [Abstract][Full Text] [Related]
9. Depletion of tumour glutathione in vivo by buthionine sulphoximine: modulation by the rate of cellular proliferation and inhibition of cancer growth.
Terradez P; Asensi M; Lasso de la Vega MC; Puertes IR; Viña J; Estrela JM
Biochem J; 1993 Jun; 292 ( Pt 2)(Pt 2):477-83. PubMed ID: 8503882
[TBL] [Abstract][Full Text] [Related]
10. [Plasma-membrane fluidity studies of murine neuroblastoma and malignant melanoma cells under irradiation].
Busse E; Zimmer G; Kornhuber B
Strahlenther Onkol; 1992 Jul; 168(7):419-22. PubMed ID: 1496453
[TBL] [Abstract][Full Text] [Related]
11. Synergistic cytotoxicity of buthionine sulfoximine (BSO) and intensive melphalan (L-PAM) for neuroblastoma cell lines established at relapse after myeloablative therapy.
Anderson CP; Reynolds CP
Bone Marrow Transplant; 2002 Aug; 30(3):135-40. PubMed ID: 12189530
[TBL] [Abstract][Full Text] [Related]
12. [Increasing chemosensitivity to cisplatin by glutathione depletion with buthionine sulfoximine. In vitro and in vivo studies with a human squamous cell cancer line].
Bier H
Laryngorhinootologie; 1990 Jan; 69(1):16-20. PubMed ID: 2310456
[TBL] [Abstract][Full Text] [Related]
13. Effect of D,L-buthionine-S,R-sulfoximine on cytotoxicity and DNA cross-linking induced by bifunctional DNA-reactive cytostatic drugs in human melanoma cells.
Hansson J; Edgren M; Ehrsson H; Ringborg U; Nilsson B
Cancer Res; 1988 Jan; 48(1):19-26. PubMed ID: 3334994
[TBL] [Abstract][Full Text] [Related]
14. Effects of glutathione depletion using buthionine sulphoximine on the cytotoxicity in mammalian cells and human tumor cells in vitro.
Jin YZ; Ding L; Shen ZF; Cai RM; Xu LM; Yang JK; Jin XQ; Lu WQ; Xu JF
Chin Med J (Engl); 1992 Aug; 105(8):647-50. PubMed ID: 1458967
[TBL] [Abstract][Full Text] [Related]
15. Modulation of glutathione level in cultured human melanoma cells.
Karg E; Brötell H; Rosengren E; Rorsman H
Acta Derm Venereol; 1989; 69(2):137-41. PubMed ID: 2564231
[TBL] [Abstract][Full Text] [Related]
16. Effects of glutathione depletion using buthionine sulphoximine on the cytotoxicity of nitroaromatic compounds in mammalian cells in vitro.
Hodgkiss RJ; Middleton RW
Biochem Pharmacol; 1985 Jun; 34(12):2175-8. PubMed ID: 4004936
[TBL] [Abstract][Full Text] [Related]
17. Selective toxicity of buthionine sulfoximine (BSO) to melanoma cells in vitro and in vivo.
Révész L; Edgren MR; Wainson AA
Int J Radiat Oncol Biol Phys; 1994 May; 29(2):403-6. PubMed ID: 8195041
[TBL] [Abstract][Full Text] [Related]
18. Effect of L-dopa methylester and glutathione depletion on murine B16BL6 melanoma growth in vitro.
Thrall BD; Meadows GG
J Invest Dermatol; 1991 Dec; 97(6):1073-7. PubMed ID: 1748817
[TBL] [Abstract][Full Text] [Related]
19. Melanoma cytotoxicity of buthionine sulfoximine (BSO) alone and in combination with 3,4-dihydroxybenzylamine and melphalan.
Prezioso JA; FitzGerald GB; Wick MM
J Invest Dermatol; 1992 Sep; 99(3):289-93. PubMed ID: 1512464
[TBL] [Abstract][Full Text] [Related]
20. In vivo therapeutic potential of combination thiol depletion and alkylating chemotherapy.
Siemann DW; Beyers KL
Br J Cancer; 1993 Dec; 68(6):1071-9. PubMed ID: 8260357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
